EGFR and non-small cell lung carcinoma: In the single-arm NCT04764214 study, patients with metastatic EGFR-mutant NSCLC received stereotactic radiotherapy (SRT) following an initial response to osimertinib, achieving a median PFS of 29.9 months and manageable toxicity [286].